<?xml version='1.0' encoding='utf-8'?>
<document id="29051147"><sentence text="Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver."><entity charOffset="91-103" id="DDI-PubMed.29051147.s1.e0" text="Rosuvastatin" /><entity charOffset="108-122" id="DDI-PubMed.29051147.s1.e1" text="Cyclosporine A" /><pair ddi="false" e1="DDI-PubMed.29051147.s1.e0" e2="DDI-PubMed.29051147.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29051147.s1.e0" e2="DDI-PubMed.29051147.s1.e1" /></sentence><sentence text="The influence of transporters on the pharmacokinetics of drugs is being increasingly recognized, and DDIs via transporters may be a risk factor for adverse events" /><sentence text=" Cyclosporine A, a strong OATP inhibitor, has been reported to increase the systemic exposure of rosuvastatin, an OATP substrate, by 7"><entity charOffset="1-15" id="DDI-PubMed.29051147.s3.e0" text="Cyclosporine A" /><entity charOffset="97-109" id="DDI-PubMed.29051147.s3.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.29051147.s3.e0" e2="DDI-PubMed.29051147.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29051147.s3.e0" e2="DDI-PubMed.29051147.s3.e1" /></sentence><sentence text="1-fold in clinical studies" /><sentence text=" PXB mice are chimeric mice with humanized livers that are highly repopulated with human hepatocytes and have been widely used for drug discovery in drug metabolism and pharmacokinetics studies" /><sentence text=" In the present study, we examined in vivo and in vitro DDIs between rosuvastatin and cyclosporine A in PXB mice and fresh human hepatocytes (PXB cells) obtained from PXB mice"><entity charOffset="69-81" id="DDI-PubMed.29051147.s6.e0" text="rosuvastatin" /><entity charOffset="86-100" id="DDI-PubMed.29051147.s6.e1" text="cyclosporine A" /><pair ddi="false" e1="DDI-PubMed.29051147.s6.e0" e2="DDI-PubMed.29051147.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29051147.s6.e0" e2="DDI-PubMed.29051147.s6.e1" /></sentence><sentence text=" We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4"><entity charOffset="51-63" id="DDI-PubMed.29051147.s7.e0" text="rosuvastatin" /></sentence><sentence text="0 μmol/l and a Vmax value of 4" /><sentence text="63 pmol/min per 106 cells" /><sentence text=" Cyclosporine A inhibited the uptake of rosuvastatin with an IC50 value of 0"><entity charOffset="1-15" id="DDI-PubMed.29051147.s10.e0" text="Cyclosporine A" /><entity charOffset="40-52" id="DDI-PubMed.29051147.s10.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.29051147.s10.e0" e2="DDI-PubMed.29051147.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29051147.s10.e0" e2="DDI-PubMed.29051147.s10.e1" /></sentence><sentence text="21 μmol/l" /><sentence text=" We then examined in vivo DDIs, and the exposure of orally administered rosuvastatin increased by 3"><entity charOffset="72-84" id="DDI-PubMed.29051147.s12.e0" text="rosuvastatin" /></sentence><sentence text="3-fold and 11-fold in PXB mice pretreated with 10 and 50 mg/kg cyclosporine A, whereas it increased by 2"><entity charOffset="63-77" id="DDI-PubMed.29051147.s13.e0" text="cyclosporine A" /></sentence><sentence text="5-fold and 6" /><sentence text="2-fold when rosuvastatin was administered intravenously, in studies that were conducted for considering gastrointestinal DDIs"><entity charOffset="12-24" id="DDI-PubMed.29051147.s15.e0" text="rosuvastatin" /></sentence><sentence text=" The liver-to-blood concentration ratio of rosuvastatin was dose-dependently decreased by pretreatment with cyclosporine A in PXB mice and SCID mice"><entity charOffset="43-55" id="DDI-PubMed.29051147.s16.e0" text="rosuvastatin" /><entity charOffset="108-122" id="DDI-PubMed.29051147.s16.e1" text="cyclosporine A" /><pair ddi="false" e1="DDI-PubMed.29051147.s16.e0" e2="DDI-PubMed.29051147.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29051147.s16.e0" e2="DDI-PubMed.29051147.s16.e1" /></sentence><sentence text=" Observed DDIs in vivo were considered to be reasonable based on the estimated concentrations of cyclosporine A at the inlet to the liver and in the liver tissues of both mice"><entity charOffset="97-111" id="DDI-PubMed.29051147.s17.e0" text="cyclosporine A" /></sentence><sentence text=" In conclusion, our results indicate that PXB mice might be a useful tool for predicting human OATP-mediated DDIs in drug discovery, and its limitation due to the differences of gastrointestinal condition from human should also be considered" /><sentence text="" /></document>